<DOC>
	<DOCNO>NCT01568775</DOCNO>
	<brief_summary>This study ass pharmacokinetics , safety tolerability aliskiren healthy subject patient End Stage Renal Disease hemodialysis .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Aliskiren ( SPP100 ) Patients With End Stage Renal Disease Hemodialysis Matched Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Female subject must nonchild bear potential , define postmenopausal woman regular menstrual bleeding least 1 year prior screen female subject surgically sterilize least 6 month prior screen . All female subject must negative pregnancy result screen . 2 . Subjects must weigh least 50 kg participate study , must body mass index ( BMI ) within range 18 30 kg/m2 3 . Vital sign 3 minute rest supine position ( lay ) within follow range : Oral body temperature 35.037.8ÂºC Systolic blood pressure , 95140 mmHg Diastolic blood pressure , 6090 mmHg Blood pressure pulse take stand position . After 3 minute stand , shall 20 mm Hg drop systolic 10 mmHg drop diastolic blood pressure associate symptomatic postural hypotension . 4 . Subjects must able communicate well investigator , understand comply requirement study . Subjects must able understand sign write informed consent . 5 . Health subject must good health determine past medical history , physical examination , vital sign assessment , electrocardiogram , laboratory test screen . 6 . Patients End Stage Renal Disease intermittent hemodialysis three time week least three month relatively good health . 1 . Smokers report cigarette use 5 cigarette per day . 2 . Use aliskiren within 2 week prior study entry . 3 . Participation clinical investigation within 3 month prior initial dosing . 4 . Hemoglobin level outside 1114 mg/dL 5 . A history/presence diabetes mellitus 6 . A past medical history arrhythmia , heart failure , unstable angina pectoris , stroke , myocardial infarction within 6 month start study . 7 . A past medical history significant electrocardiogram abnormality . 8 . Recent ( within last 3 year ) and/or recurrent history/presence autonomic dysfunction ( e.g. , recurrent episode fainting , palpitation , etc ) . 9 . Recent ( within last 3 year ) and/or recurrent history/presence acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) . 10 . Significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity aliskiren . 11 . Total white blood cell ( WBC ) count outside normal laboratory reference range . 12 . History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . 13 . A positive Hepatitis B surface antigen Hepatitis C test result . 14 . History drug alcohol abuse within 12 month prior dose , evidence abuse indicate laboratory assay conduct screen Day 1 treatment period . 15 . Consumption grapefruit grapefruit juice within 14 day prior dose . 16 . Lactating breastfeed female . 17 . History head neck angioedema . 18 . Donation loss 400 mL blood within 8 week prior initial dosing . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>aliskiren</keyword>
	<keyword>SPP100A</keyword>
</DOC>